Cadrenal Therapeutics, Inc. Common Stock (CVKD): fair value, margin of safety and Wheel Score

Is CVKD undervalued?

At 0.9700 (close of 16 Oct 2026), CVKD trades 44% below the GLS average fair value of 1.73. That average comes from 1 models run on the latest filings, and 1 of them land above the current price. Margins of safety over 30% are the exception rather than the rule across the ~7,400 stocks we value each night, so the number earns Cadrenal Therapeutics, Inc. Common Stock the full Value points in the Wheel Score - and a closer look at what the market is pricing in.

Only 1 of the nine models produced a value (DCF); the others need a dividend, positive free cash flow or positive book value the company does not have yet, so the average rests on a narrow base.

The nightly engine files CVKD under Speculative / Distressed - negative earnings or a Piotroski score of 3 or less - which caps its Wheel Score at 45 and keeps it out of the Sunday Scan.

Nine valuation models for CVKD

Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.

Quality and financial health

Financial health is weak: CVKD passes 2 of the nine Piotroski tests. Our screens drop the stock at the health rule; a low score is often the reason a stock looks cheap on the valuation models. The GLS Moat score is low at 1.7 out of 10, which says the ten-year record of revenue, earnings, margins and returns on capital has been inconsistent - growth and shocks rather than steady compounding.

Returns on capital are thin or negative - ROIC -483.3%, ROE -483.3%, ROA -305.9% - with debt at 0.00 times equity and negative free cash flow.

Cadrenal Therapeutics, Inc. Common Stock pays no dividend, so the DDM model does not apply and a covered-call holder earns only the premium and any price gain.

Institutional ownership scores 1/10, insider activity 1/10 and Congressional trading 5/10 on the GLS smart-money scales; the last recorded insider buy was on 9 Oct 2026.

Wheel Score 36: No options

CVKD has no listed options in the nightly snapshot, so there is nothing to sell and the stock cannot be wheeled however good the business; the Wheel Score is capped at 39 and shown as "No options" (36 here). The valuation and quality numbers still apply to owning the shares outright.

Volume runs at 104k shares a day on a market cap of $3M, with a beta of 1.95 - a high beta, so the stock tends to move more than the market and a strike can be gapped through; the Stability part of the Wheel Score gives that 4 of 20.

The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls; it is updated nightly and is not a recommendation. The walkthrough lesson shows how the score fits into a trade, start to finish.

Upcoming events

The next earnings report is due on 9 Nov 2026, 24 days away; a 30-45-day put sold today would expire after it, which is worth weighing against the premium.

Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.

Similar stocks in Biotechnology

The 12 companies below are the closest to Cadrenal Therapeutics, Inc. Common Stock by market cap within the Biotechnology industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.

⚖ Compare CVKD with 7 of them   All Healthcare stocks →